Keros Therapeutics
KROS
113 hedge funds and large institutions have $680M invested in Keros Therapeutics in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 25 reducing their positions, and 15 closing their positions.
192,133% more call options, than puts
Call options by funds: $5.77M | Put options by funds: $3K
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
59% more capital inflows, than outflows
Capital inflows: $75.3M | Capital outflows: $47.5M
56% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 25
9% more funds holding
Funds holding: 104 → 113 (+9)
2.03% less ownership
Funds ownership: 72.22% → 70.18% (-2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodline Partners
San Francisco,
California
|
+$11.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.14M |
| 3 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
+$5.07M |
| 4 |
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.06M |
| 5 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
-$17M |
| 2 |
Octagon Capital Advisors
New York
|
-$4.21M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$3.82M |
| 4 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.29M |
| 5 |
Morgan Stanley
New York
|
-$2.02M |
KROS Hedge Fund Activity: Q3 2022 in Review
113 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q3 2022, worth a combined $680M — up 42% from $480M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new KROS positions and 15 closed out — a net gain of 9 holders — while 39 added to existing stakes and 25 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $11.9M. The largest seller was Deep Track Capital, cutting an estimated $17M.
- 113 institutional investors held Keros Therapeutics (KROS) as of Q3 2022, up from 104 in Q2 2022.
- Funds reported $680M of Keros Therapeutics stock for Q3 2022, up 42% quarter-over-quarter.
- 24 funds opened new Keros Therapeutics positions in Q3 2022 and 15 closed out, a net change of +9 holders.
- The largest Keros Therapeutics buyer in Q3 2022 was Woodline Partners, an estimated $11.9M added.
- The largest Keros Therapeutics seller in Q3 2022 was Deep Track Capital, an estimated $17M sold.
Based on aggregated 13F filings for Q3 2022.